Ophthalmology Drugs Market worth $26.28 billion by 2030
The report "Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030", is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period.
Browse 370 market data Tables and 55 Figures spread through 328 Pages and in-depth TOC on "Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/ophthalmology-drugs-market-132608438.html
Several key factors, including the high prevalence of retinal diseases linked to aging, widespread diabetic conditions, and advanced healthcare infrastructure, contribute to this. Additionally, strong reimbursement systems, early regulatory approvals (like from the FDA), high adoption of high-value treatments, and a significant focus from key industry players also contribute to the growth of the market. A key factor for growth has been reimbursement policies that support the adoption of novel drugs in regulated markets. For instance, CMS assigned permanent J-codes within months of launch (e.g., Izervay J2782 effective Apr 2024). Medicare Part B reimburses physician-administered eye drugs, and most US/Canadian private and public plans cover branded intravitreal injections once labeled indications are met, minimizing out-of-pocket barriers and helping adoption.
However, the pervasive pricing pressures among industry stakeholders are anticipated to pose significant challenges to ongoing market development.
The intravitreal segment accounted for the largest share, by route of administration, of the ophthalmology drugs market in 2024.
Drugs administered via the intravitreal route are commonly used to treat a wide range of ophthalmological conditions. Notably, every major breakthrough medication for retinal diseases—including ranibizumab, aflibercept, faricimab, brolucizumab, pegcetacoplan, avacincaptad pegol, and dexamethasone/fluocinolone implants—has an intravitreal formulation.
Several factors contribute to intravitreal injections being the most popular method of administration for ophthalmic therapies. These include the high prevalence of retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME), the effectiveness of these injections in delivering treatment directly to the retina, and the established role of intravitreal injections in medical practice. These injections are supported by decades of research and are increasingly utilized for new therapies.
Additional factors that enhance the demand for intravitreal injections include the high frequency of treatments, reimbursement support, and the growing adoption of this method in emerging markets.
The monoclonal antibodies & fusion proteins segment commanded the largest market share in 2024.
Monoclonal antibodies & fusion proteins are leading products in the ophthalmology drugs market. Key examples include aflibercept, faricimab, bevacizumab, ranibizumab, and brolucizumab. Several factors contribute to the significant market share of these therapies, including their proven efficacy and safety, a wide range of indications, long patent life, and high cost.
These drugs are administered intravitreally and are used to treat various retinal diseases. Biologics, such as monoclonal antibodies & fusion proteins, offer the advantage of having multiple product options compared to small-molecule drugs. Given that retinal diseases are chronic, the usage of biologics tends to be higher, leading to a larger share of revenues due to the need for repeated injections.
Products like Eylea are priced at a premium and often receive favorable reimbursement. Their local delivery system results in lower systemic exposure, which is an added benefit. These treatments were some of the first to demonstrate efficacy in the retina, helping to establish physician trust in these therapies. Ongoing innovations, such as bispecific antibodies, further reinforce their dominance in the market.
North America accounted for the largest regional share of the ophthalmology drugs market in 2024.
The North American market has become the largest contributor to the ophthalmology drugs sector, driven by favorable reimbursement policies, growing investments in research and development, and an increasing burden of eye diseases. The US FDA has approved 25 drugs for various ophthalmic indications, improving patient access to treatment. This approval includes a variety of biologics and biosimilars.
Key players in the ophthalmology drugs market include Regeneron Pharmaceuticals, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bayer AG (Germany), and Novartis AG (Switzerland).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Ophthalmology Drugs Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
